Predictive Factors for Muscle Weakness in Rheumatoid Arthritis

Rheumatoid Artritte Kas Güçsüzluğu İçin Öngördürücü Faktörler

Mustafa Erkut ÖNDER, Ayşegül KILIÇARSLAN, Esra Dilek KESKİN, Hatice BODUR

Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Aksaray University Training and Research Hospital, Aksaray, Türkiye
Clinic of Physical Medicine and Rehabilitation, Maltepe Physical Therapy Center, Ankara, Türkiye
Department of Physical Medicine and Rehabilitation, Kırkkale University Faculty of Medicine, Kırkkale, Türkiye
Clinic of Physical Medicine and Rehabilitation, Ankara City Hospital, Ankara, Türkiye

ABSTRACT Objective: We aimed to determine muscle strength in patients with rheumatoid arthritis (RA) and several factors including structural joint damage that may affect decrease in muscle strength. The relations between muscle strength and quality of life and functional disability were examined. Material and Methods: Seventy five RA patients and 51 controls were involved. Demographic characteristics, body mass index, waist circumference, 25-hydroxy vitamin D, and patient global assessments of disease activity (PGA) were documented. Disease Activity Score-28 (DAS28), Visual Analog Scale-Pain (VAS-pain), Health Assessment Questionnaire (HAQ) and the Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL) were calculated. Radiographs of the hands were evaluated by van der Heijde modified Sharp score (vdHSS). Grip strength of both hands was measured by Jamar dynamometer. Results: Demographics (age, gender) were not different between RA patients and control group. Grip strength of patients with RA (22.79±18.58) was lower than control group (26.00±11.25, p=0.04). There was a significant correlation with grip strength and disease duration, tender joint count, VAS-pain, PGA, DAS28, HAQ, RAQoL, erosion and narrowing score (p<0.05). Conclusion: This study showed that RA obtains decreased muscle strength, impaired function and quality of life. Joint space narrowing and disease activity are the main parameters that affect muscle strength.

KEYWORDS: Muscle strength; body mass index; quality of life

ÖZET Amaç: Romatoid artritten (RA) hastalarda, kas kuvvetini değerlandırımı ve kas kuvvetindeki azalmayı etkileyebilecek yapısal ve dahiç çeşitli faktörleri belirlemeyi amaçladık. Bu çalışmada, kas gücü ile yaşam kalitesi ve fonksiyonel yetenekler arasındaki ilişkiye incelenmiştir.

Gereç ve Yöntemler: Yetmiş beş RA hastası ve 51 kontrol alındı. Demografik özellikler, beden kitle indeksi, boy çevresi, 25-hidroksi vitamin D, ve hastanın global değerlendirmesi (PGA) belgelenmiştir. Radyografiler, vandér Heijde modifiye Sharp skoru (vdHSS) ile değerlendirilmiştir. Jamar dynamometre ile iki elin kavrama gücü ölçülüdür. Sonuç: Klinik özellikler (yas, cinsiyet) RA hastaları ve kontrol grubu arasında farklı değişti. Hasta kivrakma gücü (22,79±18,58) kontrol grubundan düşükti (26,00±11,25, p=0,04). Kivrakma gücü ile hastalık süresi, “tender joint count”, VAS-pain, PGA, DAS28, HAQ, RAQoL, erozyon ve daralma skorunda anlamlı korelasyon vardı (p<0,05). Bu çalışmada, RA’nın kas güçünün azaltığını ve fonksiyonel yeteneklerin de yaşaman kaliteinde bozulması neden olduğunu göstermiştir. Eklentili ve hastalık aktiviteleri kas gücünün etkileyen ana parametrelerdir.

Rheumatoid arthritis (RA) is a well-known autoimmune inflammatory disease that influences articular, periarticular structures and synovial membrane. The connective tissue inflammation induces progressive disability. The most frequently affected components in RA are hands. Progressive hand dysfunction causes various limitations in patients’ daily life activities, functions, and quality of life likewise social aspects of life.

Correspondence: Mustafa Erkut ÖNDER
Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Aksaray University Training and Research Hospital, Aksaray, Türkiye
E-mail: erkunder@hotma.com

Peer review under responsibility of Journal of Physical Medicine and Rehabilitation Science.

Received: 11 Nov 2021 Received in revised form: 24 Dec 2021 Accepted: 27 Dec 2021 Available online: 05 Jan 2022

This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Sarcopenia is characterized as the reduction of muscle mass and strength. The diagnosis, identified by the European Working Group on Sarcopenia in Older People, includes dual energy X-ray absorptiometry, walking speed and handgrip strength measurements. Handgrip strength that can be measured by a dynamometer is usually accepted as sarcopenia scanning method and it is correlated with muscle strength in other body parts.

Chronic inflammation can stimulate metabolic changes; protein catabolism and whole-body protein break down. Therefore, patients with RA have changes in their muscle mass and fat mass components. The loss of muscle mass is named as rheumatoid cachexia and can be associated with an increase in fat mass. Weight loss may accompany increased or stable fat mass. Muscle weakness and loss of muscle mass as well as joint damage are notable features in these patients. Lower muscle mass, increased intramuscular fat content, physical inactivity due to the pain and joint deformities enhance muscle weakness in patients with RA. On the other side, decreased muscle strength leads more physical inactivity, disability and deterioration in quality of life.

Disease activity, joint deformities, age, and physical inactivity are considered to play a role in muscle weakness except for the body-fat distribution. In the current report, we aimed to assess muscle strength in RA patients and the association between functional disability, quality of life and muscle strength. Moreover, we purposed to examine several factors including structural joint damage that may affect the muscle weakness.

MATERIAL AND METHODS

Our cross-sectional trial was planned in a physical medicine and rehabilitation outpatient clinic. Written informed consent has been received from all of the patients and controls. The study was approved by Ankara Numune Training and Research Hospital Scientific and Medical Research Ethics Committee (Decision no/date: 2014-727/3.1.2014). The study agreed with the World Medical Association’s Declaration of Helsinki.

Seventy-five RA patients who met the American College of Rheumatology and European League Against Rheumatology 2010 classification criteria for RA and 51 controls that were similar in terms of gender distribution and age were involved in the study.

Exclusion criteria were: <18-year-old, trauma, fracture or upper extremity nerve damage affecting hand functions, severe cognitive and neurological problems (stroke, multiple sclerosis, amyotrophic lateral sclerosis etc.), active cancer, and receiving any antidepressant medication in the last one year.

Demographic characteristics, body mass index (BMI), waist circumference, duration of disease and morning stiffness, tender joint count (TJC) and swollen joint count, erythrocyte sedimentation rates, C-reactive protein, 25 hydroxi vitamin D [25(OH)D] patient global assessments of disease activity (PGA) were documented. Receiving disease modifying antirheumatic drugs (DMARD) was recorded.

Disease Activity Score-28 (DAS28) and 10 cm Visual Analog Scale-Pain (VAS-pain) were used to specify disease activity and pain severity. Health Assessment Questionnaire (HAQ) and Rheumatoid arthritis Quality of Life Questionnaire (RAQoL) results recorded to assess functional status and the health-related quality of life.

Van der Heijde modified Sharp score (vdHSS) was considered to evaluate the changes in posteroanterior hand X-rays, joint space narrowing and erosion score were determined.

Grip strength of both hands measured by Jamar dynamometer in the sitting position, and the shoulder was in neutral rotation and adduction, the elbow was in 90° flexion, the wrist in the neutral position. In the test procedure, three measurements were made with a minute interval between each measurement for hand grip strength and averages were recorded.

Normality was tested with Shapiro-Wilk test. General descriptive statistics are summarized as mean, standard deviation, median, minimum-maximum, number and frequencies. Independent samples t-test or Mann-Whitney U test were used to compare groups. Homogeneity of the distributions of categorical variables was determined using chi-square tests. Spearman correlation coefficient was used and the correlation coefficient ranges in value from -1 to +1. Coefficients determined negligible, weak, moderate,
strong, and very strong correlation (0-0.10; 0.10-0.39; 0.40-0.69; 0.70-0.89; 0.90-1.00 respectively). Significant predictors for grip strength were evaluated with univariate analyses and at least moderately significant variables were selected for multivariate linear regression analyses. Backward method is used in the selection of variables. A value of p<0.05 was considered statistically significant. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY, USA: IBM Corp. software was used for all these analyses.

RESULTS

Seventy-five RA patients with a mean age of 51.96±12.82 years and 51 controls with a mean age of 54.84±10.16 were recorded for the study. Gender distribution and mean age were not different between RA and control groups (p>0.05). In RA group, waist circumference and BMI measurements were higher and 25(OH)D levels were lower than controls. Grip strength of healthy controls was higher than RA patients (Table 1).

All of the patients with RA continued to follow-up visit regularly at least one year. Duration of disease was 24-420 months. 56 (74.66%) patients were using conventional DMARD, 9 (12%) patients were using biological DMARD and 10 patients were using corticosteroids and/or analgesics. DAS28 results indicated that 32 (42.7%) RA patients were in remission, 7 (9.3%) had low disease activity, 28 (37.3%) had moderate disease activity and 8 (10.7%) had severe disease activity, and 28 (37.33%) RA patients had no pain on their joints. Disease activity parameters, vDHSS, HAQ and RAQoL results of patients with RA were summarized in Table 2.

The handgrip strength differences between medication types (corticosteroid users, biological and conventional DMARD) were analyzed. Handgrip strength was 37.01±40.42 and 34.05±33.05 in corticosteroid users; 32.22±12.01 and 36.11±15.76 in biological DMARD users; 30.33±19.43 and 29.91±19.59 in conventional DMARD users (right- and left-hand measures respectively) The difference was not significant between medication types (p=0.687; p=0.654 right and left hand respectively)

Relationships between grip strength and clinical variables were analyzed. There were significant correlation with disease duration, TJC, VAS-pain, PGA, DAS28, HAQ, RAQoL, erosion and narrowing score (Table 3).

| TABLE 1: Demographic and clinical features of rheumatoid arthritis patients and controls. |
|---------------------------------------------------------------|
| **Age (years, mean±SD)** | **Rheumatoid arthritis n=75** | **Controls n=51** | **p value** |
|---------------------------|-----------------------------|------------------|------------|
| Gender, n (%)             | 51.96±12.82                 | 54.84±10.16      | 0.174      |
| Female                    | 56 (74.7)                   | 40 (78.4)        | 0.626      |
| Male                      | 19 (25.3)                   | 11 (21.6)        |            |
| **Body mass index**       |                             |                  |            |
| (kg/m², mean±SD)          | 28.85±6.45                  | 26.14±4.12       | 0.029*     |
| Waist circumference (cm, mean±SD) | 95.73±15.72            | 87.05±18.79      | 0.041*     |
| **Serum 25(OH)D**         | 11.72±7.63                  | 17.58±10.48      | 0.003*     |
| Median (minimum-maximum)  | 10.67 (3-35.40)             | 14.48 (4.17-44)  |            |
| **Grip strength, right**  | 24.19±20.85                 | 26.60±11.12      | 0.031*     |
| Median (min-max)          | 20 (2-40)                   | 25 (10-60)       |            |
| **Grip strength, left**   | 22.79±18.58                 | 26.00±11.25      | 0.039*     |
| Median (minimum-maximum)  | 20 (2-40)                   | 25 (10-60)       |            |

*p<0.05; SD: Standard deviation; 25(OH)D: 25 hydroxi vitamin D.
We determined significant predictors for grip strength with using multivariate analyses. Only two variables, DAS28 and erosion score were associated with grip strength. Results were shown in Table 4.

**DISCUSSION**

In the current report, we aimed to explore hand grip strength in RA patients and healthy participants and to analyze the predictors for decreased muscle strength in RA. Our results supported that RA patients had decreased muscle strength and the most important factors of muscle weakness were joint space narrowing and disease activity.

Muscle dysfunctions are frequently observed problems in RA, and these dysfunctions are associated with pain, atrophy, reflex inhibition, myopathy, and psychological factors. The decrease in the level of physical activity leads to morphological changes such as muscle strength loss and increase in muscle fiber length, decrease in capillary density and increase in intramuscular connective tissue. In addition, tumor necrosis factor alpha (TNF-α) and other inflammatory cytokines also act as catabolic mediators. Schaap et al. showed that TNF-α and its soluble mediators were related with muscle weakness and muscle mass in elderly. Secondary sarcopenia can be seen frequently in patients with RA due to active cytokines, oxidative stress, chronic inflammation, and physical inactivity. Patients with RA have higher protein destruction and sarcopenia that were

| TABLE 2: Disease activity, functional assessment and quality of life in patients with rheumatoid arthritis. |
|-----------------------------------|-------------------------------|
| Patients with rheumatoid arthritis n=75 |
| Disease duration (months, mean±SD) 133.72±91.02 |
| Median (minimum-maximum) 120 (24-420) |
| Erythrocyte sedimentation rate (mm/h, mean±SD) 20.54±12.31 |
| Median (minimum-maximum) 20 (2-57) |
| C-reactive protein (mg/L, mean±SD) 11.77±15.20 |
| Median (minimum-maximum) 6.67 (0.20-72.7) |
| Pain-VAS (mm, mean±SD) 3.56±2.91 |
| Median (minimum-maximum) 3 (0-10) |
| PGA-VAS (mm, mean±SD) 3.04±2.85 |
| Median (minimum-maximum) 3 (0-10) |
| TJC count (mean±SD) 10.48±14.11 |
| Median (minimum-maximum) 4 (0-28) |
| SJC count (mean±SD) 0.52±1.33 |
| Median (minimum-maximum) 0 (0-8) |
| DAS28 (mean±SD) 3.21±1.37 |
| Anti-rheumatic drugs n (%) |
| Conventional DMARD 56 (74.66) |
| Biologic DMARD 9 (12) |
| Corticosteroids (only) 7 (9.33) |
| None 3 (4) |
| HAQ (mean±SD) 0.92±0.79 |
| Median (minimum-maximum) 0.75 (0-2.75) |
| RAQoL (mean±SD) 12.10±10.43 |
| Median (minimum-maximum) 11 (0-29) |
| vdHSS (erosion) 6.77±12.07 |
| Median (minimum-maximum) 2 (0-62) |
| vdHSS (narrowing) 16.82±11.71 |
| Median (minimum-maximum) 14 (0-91) |

SD: Standard deviation; VAS: Visual Analog Scale; PGA: Patient global assessments of disease activity; DAS28: Disease Activity Score-28; DMARD: Disease modifying antirheumatic drugs; HAQ: Health Assessment Questionnaire; RAQoL: Rheumatoid arthritis Quality of Life Questionnaire; vdHSS: van der Heijde modified Sharp score.

**TABLE 3: Correlations between grip strength and clinical variables.**

| Age | -0.71 | 0.542 |
| Body mass index (kg/m²) | -0.16 | 0.151 |
| Waist circumference (cm) | -0.13 | 0.262 |
| Disease duration | -0.22 | 0.044* |
| ESR | -0.09 | 0.443 |
| CRP | -0.13 | 0.248 |
| 25(OH)D ng/mL | 0.12 | 0.333 |
| TJC | -0.26 | 0.024* |
| SJC | -0.12 | 0.268 |
| Morning stiffness | -0.22 | 0.052 |
| VAS pain | -0.23 | 0.044* |
| PGA | -0.31 | 0.002* |
| DAS28 | -0.33 | 0.006* |
| HAQ | -0.41 | 0.005* |
| RAQoL | -0.41 | <0.001* |
| vdHSS (erosion) | -0.31 | 0.018* |
| vdHSS (narrowing) | -0.38 | 0.003* |

*p<0.05; ESR: Erythrocyte sedimentation rates; CRP: C-reactive protein; 25(OH)D: 25 hydroxi vitamin D; TJC: Tender joint count; SJC: Swollen joint count; VAS: Visual Analog Scale; PGA: Patient Global Assessment; DAS28: Disease Activity Score-28; HAQ: Health Assessment Questionnaire; RAQoL: Rheumatoid arthritis Quality of Life Questionnaire; vdHSS: van der Heijde modified Sharp score.
affected by cytokines like TNF-α and interleukin 6. In this sense, blocking TNF-α and interleukin 6 with biological DMARD may provide the protein catabolism. Although glucocorticoid use is known to be a risk for sarcopenia with its known myopathy side effect and its impact on muscle and adipose tissue distribution, anti-inflammatory effects will prevent protein catabolism caused by cytokines. Muscle strength in patients with RA has been found lower than healthy controls and decrease in muscle strength can be seen from the early stages of this disease. Our results confirm that RA patients have decreased muscle strength which was evaluated by hand dynamometer. Our study, no relationship was found between the medications used in patients with RA and hand grip strength. Similarly, the lack of a causal relationship between glucocorticoid use and sarcopenia in the study of Torii et al. supports the contradictory effects of steroids on the sarcopenia mechanism.

Muscle mass is important for patients because it is the main protein source of body and, supports the adaptation to metabolic stress. Body composition, especially fat and mass composition, may change in RA patients. This disease may lead a complex metabolic syndrome which is accompanied with muscle loss without weight loss. Our findings referred that RA patients had higher BMI and waist circumference than healthy controls although they had decreased muscle strength. This result supports that RA changes body fat and muscle composition, and has an effect on increasing fat/muscle ratio.

It is known that vitamin D has effects on preadipocyte differentiation and may affect muscle-fat tissue distribution. In addition, it has been suggested that vitamin D supplementation causes an increase in muscle strength and muscle mass, and may be beneficial in the prevention of sarcopenia. This study did not reveal a causal relationship between sarcopenia and vitamin D deficiency in patients with RA. It was thought that the low level of vitamin D in patients in general may be a factor on these results.

Hand grip strength is crucial for many of the daily living activities and informs about the patients’ functionality. Dysfunction of hands, which are the most frequently and seriously affected joints in RA, and this is the main reason of disability. Bodur et al. determined that pinch measurements, grip strength, disease activity indicators were associated with hand disability. They reported that there was a stronger relationship between grip strength and hand function. Several studies argued that grip strength was related with functional impairment and disability in RA patients. Similarly in the present study, grip strength was negatively correlated with functionality. Moreover, our outcomes demonstrated an association among the grip strength and, VAS pain, disease duration quality of life, PGA, TJC, disease activity, and structural damage. It is naturally expected that the pain parameters associated with muscle strength and longer disease duration may lead more physical inactivity and more severe structural damage which decrease muscle strength. On the other hand, multivariate regression analyses showed that only 2 parameters have an effect on muscle strength. These parameters were DAS28 and joint space narrowing score. In these outcomes, increased protein catabolism of the active disease with TNF pathway appears to be effective rather than being associated with pain or disease duration. Erol et al., findings supported the effect of disease activity on muscle strength. In their study, grip strength was significantly associated with bone edema and tenosynovitis score on magnetic resonance imaging. RA is a chronic disease that induces decrease in the quality of life as a result of

| Grip strength | DAS28 | vdHSS joint space narrowing |
|---------------|-------|-----------------------------|
|               | B     | SE  | p value | 95% CI   |
| DAS28         | -5.28 | 2.47 | 0.036   | -10.25 -0.31 |
| vdHSS joint space narrowing | -0.67 | 0.20 | <0.005 | -1.08 -0.27 |

TABLE 4: Relationship between clinical predictors and grip strength.

DAS28: Disease Activity Score-28; vdHSS: van der Heijde modified Sharp score; R²: Coefficient of determination; B: Regression coefficient; SE: Standard error; CI: Confidence interval.
several factors. These factors, which are closely related to each other, also appear to involve muscle weakness.

According to our knowledge, this is the first study that explored the relationship with grip strength and vdhSS. We found that joint space narrowing has a notable influence on muscle strength. Various studies determined that decrease in hand joints’ range of motion was related with muscle strength.21,27 It is thought that the joint space narrowing seen in the direct graphs, joint damage, and limitation of movement may cause a decrease in muscle strength.

Limitations of our report were: The cross-sectional plan, which does not enable for appreciation of the temporal changes due to disease. Systemic parameters (such as cardiac, bone mineral densitometry) that may be associated with sarcopenia were not included. Hand grip strength, which is a very good predictor of sarcopenia, was measured, but sarcopenia was not classified according to the European Working Group on Sarcopenia in Older People criteria. Therefore, longitudinal studies in larger samples are required to corroborate our preliminary findings.

CONCLUSION

Our study supported that RA obtains decreased muscle strength, impaired functionality and quality of life. Joint space narrowing and disease activity are the main parameters that affect muscle strength. Muscle loss may lead impaired functionality and quality of life for RA patients.

REFERENCES

1. Kajtžopoulos-Ofrnovska K, Sadura-Sieklocka T, Kasparčak K, et al. The beneficial effects of rehabilitation on hand function in patients with rheumatoid arthritis. Reumatologia. 2016;54: 285-90. [Crossref] [PubMed] [PMC]
2. Brooks JM, Titus AJ, Bruce ML, et al. Depression and Handgrip Strength Among U.S. Adults Aged 60 Years and Older from NHANES 2011-2014. J Nutr Health Aging. 2018;22:938-43. [Crossref] [PubMed] [PMC]
3. Riviat N, Sethai S, Lakami PW, et al. Factors related with handgrip strength in elderly patients. Acta Med Indones. 2017;49:215-9. [PubMed] [PMC]
4. Moreira VG, Perez M, Lourenço RA. Prevalence of sarcopenia and its associated factors: the impact of muscle mass, gait speed, and handgrip strength reference values on reported frequencies. Clinics (Sao Paulo). 2019;74:e477. [Crossref] [PubMed] [PMC]
5. Summers GD, Metios GS, Stavroulakis-Kalinoglou A, et al. Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol. 2010;6:465-61. [Crossref] [PubMed] [PMC]
6. Udels T, Kustiainen HU, Häkkänen KH. Decreasing muscle performance associated with increasing disease activity in patients with rheumatoid arthritis, PLoS One. 2018;13:e0194917. [Crossref] [PubMed] [PMC]
7. Santillán-Díaz C, Ramírez-Sánchez N, Espinosa-Morales R, et al. Prevalence of rheumatoid cachexia assessed by bioelectrical impedance vector analysis and its relation with physical function. Clin Rheumatol. 2018;37:607-14. [Crossref] [PubMed]
8. da Rocha OM, de Almeida Pedoli Batista A, Maestá N, et al. Sarcopenia in rheumatoid cachexia: definition, mechanisms, clinical consequences and potential therapies. Revista Brasileira de Reumatologia. 2009;49:288-301. [Crossref] [PubMed]
9. Baker JF, Von Feldt J, Mostouf-Mob S, et al. Deficits in muscle mass, muscle density, and modified associations with fat in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:1612-8. [Crossref] [PubMed] [PMC]
10. Sokka T, Häkkänen A, Kautiainen H, et al; QUEST-RA Group. Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum. 2008;59:42-50. [Crossref] [PubMed] [PMC]
11. Yamada T, Steinz MM, Kenne E, et al. Muscle weakness in rheumatoid arthritis: the role of Ca2+ and free radical signaling. EBioMedicine. 2017;23:12-19. [Crossref] [PubMed] [PMC]
12. Erol-AM, Ceceli E, Uysal Ramadan S, et al. Effect of rheumatoid arthritis on strength, dexterity, coordination and functional status of the hand: the relationship with magnetic resonance imaging findings. Acta Reumatol Port. 2016;41:328-37. English. [PubMed] [PMC]
13. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81. [PubMed]
14. Prevo M, van’t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-8. [PubMed] [PMC]
15. Price DD, McGrath PA, Raff A, et al. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain. 1983;17:45-56. [Crossref] [PubMed] [PMC]
16. Kujčikovec AA, Sahin H, Ataman S, et al. Issues in cross-cultural validity: example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum. 2004;51:14-9. [Crossref] [PubMed] [PMC]
17. Kutluy S, Kujčikovec AA, Görlü D, et al. Adaptation and validation of the Turkish version of the Rheumatoid Arthritis Quality of Life Scale. Rheumatol Int. 2003;23:216-21. [Crossref] [PubMed] [PMC]
18. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261-3. [PubMed] [PMC]
19. Sheehy C, Gaffney K, Mukhtyar C. Standardized grip strength as an outcome measure in early rheumatoid arthritis. Scand J Rheumatol. 2013;42:289-93. [Crossref] [PubMed]
20. Uchitomi R, Oyabu M, Kamoi Y. Vitamin D and sarcopenia: Potential of Vitamin D supplementation in sarcopenia prevention and treatment. Nutrients. 2020;12:3185. [Crossref] [PubMed] [PMC]
21. Özeri Z, Çakşkın S ve ark. [The relationships among functional impairment, disability and articular damage in rheumatoid hand]. FTR Bİ Der JPMR Sci. 2008;2:53-8.
22. Bodur H, Yilmaz O, Keskin D. Hand disability and related variables in patients with rheumatoid arthritis. Rheumatol Int. 2006;26:541-4. [Crossref] [PubMed]
23. Schöff P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126:1780-3. [Crossref] [PubMed] [PMC]
24. Schaap LA, Pluijm SM, Deeg DJ, et al; Health ABC Study. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009;64:1183-9. [Crossref] [PubMed] [PMC]
25. Tori M, Hashimoto M, Hanai A, et al. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29:569-95. [Crossref] [PubMed] [PMC]
26. Beenakker KG, Ling CH, Meskers CG, et al. Patterns of muscle strength loss with age in the general population and patients with a chronic inflammatory state. Ageing Res Rev. 2010;9:431-6. [Crossref] [PubMed] [PMC]
27. Sheehy C, Gaffney K, Mukhtyar C. Standardized grip strength as an outcome measure in early rheumatoid arthritis. Scand J Rheumatol. 2013;42:289-93. [Crossref] [PubMed] [PMC]